A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s Disease
Matthieu Allez(Inserm), Taku Kobayashi(Kanazawa University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Rory Rebuck(Janssen (United States)), Bin Zou(Janssen (United States)), Brian G. Feagan(Western University), Charles Randall, Geert D’Haens(Amsterdam University Medical Centers), Nina Chi-Sabins(Springhouse), Mark Curran(Janssen (United States)), Christopher O’Brien(Janssen (United States)), Thomas Baker(Janssen (United States)), Gert De Hertogh(KU Leuven), Jewel Johanns(Johnson & Johnson (United States)), Mei‐Lun Wang(Children's Hospital of Philadelphia)
Cited by 11
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k